{"id":7806,"date":"2023-11-06T18:30:13","date_gmt":"2023-11-06T15:30:13","guid":{"rendered":"https:\/\/egemhabertv.com\/?p=7806"},"modified":"2023-11-06T18:30:13","modified_gmt":"2023-11-06T15:30:13","slug":"biontech-gelir-tahminini-4-milyar-avroya-dusurdu","status":"publish","type":"post","link":"https:\/\/egemhabertv.com\/?p=7806","title":{"rendered":"BioNTech gelir tahminini 4 milyar avroya d\u00fc\u015f\u00fcrd\u00fc"},"content":{"rendered":"

[ad_1]
\n
<\/p>\n

\n

BioNTech, 2023’\u00fcn \u00fc\u00e7\u00fcnc\u00fc \u00e7eyre\u011fine ili\u015fkin finansal sonu\u00e7lar\u0131n\u0131 a\u00e7\u0131klad\u0131. Buna g\u00f6re \u015firketin \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrekteki net kar\u0131, ge\u00e7en y\u0131l\u0131n ayn\u0131 d\u00f6nemine k\u0131yasla y\u00fczde 91 d\u00fc\u015ferek 160,6 milyon avroya geriledi. BioNTech, ge\u00e7en y\u0131l\u0131n temmuz-eyl\u00fcl d\u00f6neminde 1 milyar 784 milyon avro kar a\u00e7\u0131klam\u0131\u015ft\u0131.<\/p>\n

BioNTech\u2019in ABD’li orta\u011f\u0131 Pfizer veya ABD’li rakibi Moderna’n\u0131n aksine \u00fc\u00e7\u00fcnc\u00fc \u00e7eyre\u011fin sonunda kar a\u00e7\u0131klamas\u0131 dikkati \u00e7ekti.<\/p>\n

\u015eirketin gelirleri, \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrekte 2022’nin ayn\u0131 d\u00f6nemine g\u00f6re y\u00fczde 74\u2019ten fazla azalarak 895,3 milyon avroya indi. BioNTech, ge\u00e7en y\u0131l\u0131n \u00fc\u00e7\u00fcnc\u00fc \u00e7eyre\u011finde 3 milyar 461,2 milyon avro gelir elde etmi\u015fti.<\/p>\n

BioNTech Mali \u0130\u015fler M\u00fcd\u00fcr\u00fc (CFO) Jens Holstein, BioNTech’in \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrekte kar a\u00e7\u0131klayabilmesinin temel nedeninin Pfizer ve di\u011fer \u015firketlerle kurulan, kar ve maliyetlerin payla\u015f\u0131ld\u0131\u011f\u0131 ortakl\u0131k modeli oldu\u011funu belirtti.<\/p>\n

Holstein, “B\u00fcy\u00fck ila\u00e7 \u015firketleriyle olan stratejik i\u015fbirli\u011fi modelimiz, ila\u00e7lar\u0131 geli\u015ftirmemize ve geni\u015f \u00e7apta ticarile\u015ftirmemize yard\u0131mc\u0131 olurken bize ek finansal esneklik sa\u011fl\u0131yor.” dedi.<\/p>\n

\u015eirketin Ocak-Eyl\u00fcl 2023’teki gelirleri 7,15 milyar avro ve net kar\u0131 da 472,4 milyon avro olarak a\u00e7\u0131kland\u0131.<\/p>\n

Kovid-19 a\u015f\u0131s\u0131 sat\u0131\u015flar\u0131ndaki azal\u0131\u015f nedeniyle daha \u00f6nce 5 milyar avro olan y\u0131ll\u0131k bazda gelir beklentisi 4 milyar avroya d\u00fc\u015f\u00fcr\u00fcld\u00fc. \u015eirket, ge\u00e7en y\u0131l b\u00fcy\u00fck \u00e7o\u011funlu\u011fu Kovid-19 a\u015f\u0131s\u0131 sat\u0131\u015f\u0131ndan olmak \u00fczere 17,2 milyar avro gelir elde etmi\u015fti.<\/p>\n

mRNA teknolojisiyle Kovid-19 a\u015f\u0131s\u0131n\u0131 ilk piyasaya s\u00fcren BioNTech, anti-kanser ila\u00e7lar\u0131na odaklan\u0131yor. Akci\u011fer kanserine kar\u015f\u0131 “BNT316” adl\u0131 ila\u00e7 aday\u0131na y\u00f6nelik faz 3 \u00e7al\u0131\u015fmas\u0131, Haziran 2023\u2019ten beri y\u00fcr\u00fct\u00fcl\u00fcyor. BioNTech, ayn\u0131 zamanda antikor-ila\u00e7 konjugatlar\u0131 (ADC) olarak adland\u0131r\u0131lan ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccrelerine dayal\u0131 tedaviler \u00fczerinde de \u00e7al\u0131\u015fmalar yap\u0131yor. Bu teknolojinin kemoterapinin yerini alma potansiyelinin oldu\u011fu belirtiliyor.<\/p>\n

\u00d6te yandan \u015firket, gelir beklentilerinin azalmas\u0131yla 2023 AR-GE b\u00fct\u00e7esini ikinci kez d\u00fc\u015f\u00fcrerek 2 ila 2,2 milyar avrodan 1,8 ila 2 milyar avro aral\u0131\u011f\u0131na revize etti.<\/p>\n<\/p><\/div>\n

[ad_2]
\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

[ad_1] BioNTech, 2023’\u00fcn \u00fc\u00e7\u00fcnc\u00fc \u00e7eyre\u011fine ili\u015fkin finansal sonu\u00e7lar\u0131n\u0131 a\u00e7\u0131klad\u0131. Buna g\u00f6re \u015firketin \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrekteki net<\/p>\n","protected":false},"author":1,"featured_media":7807,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-7806","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-spor"],"_links":{"self":[{"href":"https:\/\/egemhabertv.com\/index.php?rest_route=\/wp\/v2\/posts\/7806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/egemhabertv.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/egemhabertv.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/egemhabertv.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/egemhabertv.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7806"}],"version-history":[{"count":0,"href":"https:\/\/egemhabertv.com\/index.php?rest_route=\/wp\/v2\/posts\/7806\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/egemhabertv.com\/index.php?rest_route=\/wp\/v2\/media\/7807"}],"wp:attachment":[{"href":"https:\/\/egemhabertv.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/egemhabertv.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/egemhabertv.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}